Search results for CD13

Ultra-LEAF™ Purified anti-human CD13 Antibody anti-CD13 - WM15, BioLegend, 301723

Additional reported applications (for the relevant formats) include: inhibition of tumor-cell invasion and blocking of aminopeptidase activities2,3, and immunohistochemical staining of acetone-fixed frozen tissue sections5. WM15 does not recognize formalin-fixed or paraffin-embedded tissue sections5. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301708). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301723 and 301724) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Ultra-LEAF™ Purified anti-human CD13 Antibody anti-CD13 - WM15, BioLegend, 301724

Additional reported applications (for the relevant formats) include: inhibition of tumor-cell invasion and blocking of aminopeptidase activities2,3, and immunohistochemical staining of acetone-fixed frozen tissue sections5. WM15 does not recognize formalin-fixed or paraffin-embedded tissue sections5. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301708). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301723 and 301724) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Brilliant Violet 605™ anti-human CD13 Antibody anti-CD13 - WM15, BioLegend, 301727

Additional reported applications (for the relevant formats) include: inhibition of tumor-cell invasion and blocking of aminopeptidase activities2,3, and immunohistochemical staining of acetone-fixed frozen tissue sections5. WM15 does not recognize formalin-fixed or paraffin-embedded tissue sections5. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301708). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301723 and 301724) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Brilliant Violet 605™ anti-human CD13 Antibody anti-CD13 - WM15, BioLegend, 301728

Additional reported applications (for the relevant formats) include: inhibition of tumor-cell invasion and blocking of aminopeptidase activities2,3, and immunohistochemical staining of acetone-fixed frozen tissue sections5. WM15 does not recognize formalin-fixed or paraffin-embedded tissue sections5. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 301708). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 301723 and 301724) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

CD13, Mouse, mAb ER-BMDM1, Hycult Biotech, HM1083

The monoclonal antibody ER-BMDM1 is directed against a 160-kDa cell membrane-associated antigen with aminopeptidase N activity. Aminopeptidase N (APN) is also known as Alanyl Aminopeptidase (ANPEP), CD13 antigen or membrane protein p161. The protein consists of a short cyplasmic tail, a transmembrane region, a Ser/Thr region, and a zinc metalloproteinase domain. Widely expressed in many cells, tissues, and species, aminopeptidase N cleaves the N-terminal amino acids from bioactive peptides, leading to their inactivation or degradation. It has putative involvement in several biological processes including antigen processing and presentation, cell adhesion, tumor invasion and metastasis and neurotransmitter degradation. The antigen recognized by the monoclonal antibody ER-BMDM1 is present on various mouse macrophage and dendritic cell subpopulations as well as on microvillous epithelia. The ER-BMDM1 antigen is expressed at increasing levels upon maturation of macrophages. Therefore the monoclonal antibody ER-BMDM1 is a useful marker for the identification of aminopeptidase N positive macrophages and dendritic cells in mouse, the expression of the ER-BMDM1 antigen arises after the monocytic stage of differentation: bone marrow cells and peripheral blood monocytes are ER-BMDM1 negative, whereas mature macrophages express the ER-BMDM1 antigen. A subpopulation of dendrocytes and their in vitro equivalents, the dendritic cells, are also ER-BMDM1 positive.

Biotin Anti-CD13 antibody [EPR4058], Abcam, AB197630

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Biotin Anti-CD13 antibody [WM15], Abcam, AB130430

Anti-Pig CD13 Polyclonal Antibody, AntibodySystem, PPD08901

Anti-CD13 antibody [EPR27472-288], Abcam, AB317440

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CD13 antibody [R3-63], Abcam, AB33489

Clone R3-63 has been reported to block mouse APN enzyme activity.